Ignyta
Biotechnology company catalyzing personalized medicine in autoimmune diseases.
Launch date
Market cap
-
Enterprise valuation
$216—324m (Dealroom.co estimates Dec 2013.)
San Diego California (HQ)
Financials
Estimates*
EUR | 2015 | 2016 |
---|---|---|
R&D budget | 68.0m | 73.0m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
$5.5m | Series B | ||
N/A | $1.0m | Debt | |
N/A | $54.0m | Early VC | |
$10.0m | Debt | ||
N/A | $55.2m | IPO | |
$31.0m | Post IPO Debt | ||
$42.0m | Post IPO Debt | ||
N/A | $30.0m | Post IPO Equity | |
$42.0m | Post IPO Debt | ||
N/A | $160m | Post IPO Equity | |
$1.7b | Acquisition | ||
Total Funding | $59.5m |
Related Content
Recent News about Ignyta
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.